Safety, Efficacy of Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta Analysis

Assiut University2,000 enrolled

Overview

Since the beginning of COVID-19 pandemic, a safe and effective vaccine against infection and development of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed control of the wide spread of COVID-19 and reduce death rates throughout the world. Many clinical trials investigated the immunogenicity of different proposed vaccine including the first distributed vaccine; the ChAdOx1 nCoV-19 vaccine and there is a need to analyze the results of published clinical trials.

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

ChAdOx1 nCoV-19 Vaccine

Interventions

ChAdOx1 nCoV-19 vaccineOTHER

covid-19 vaccine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant who received 2 doses of ChAdOx1 nCoV-19 vaccine Exclusion Criteria: * non vaccinated person

Locations (1)

Aliae AR Mohamed-Hussein

Asyut, Egypt

Outcomes

Primary Outcomes

To evaluate the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis

the frequency of breakthrough COVID-19 infection

Time frame: up to one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.